Sunday 11 October 2026 Export all AMGN data to Excel Powerpack

Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

414.87 7.43 +1.82%
Market cap
$220.3B
P/E
25.6×
Fwd P/E
22.7×
Dividend yield
2.40%
F-score
7/9
Altman Z
1.69
Beneish M
−2.27
Dividend safety
56/100

Amgen Inc. (AMGN) EV/FCF

Alert me on EV/FCF

As of 9 October 2026, Amgen Inc. (AMGN) trades at a EV/FCF of 27.4×. Over the past ten years it has ranged from 10.7× (September 2015) to 46.5× (September 2024); the current reading is higher than 87% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 28.9× 53.05%
FY2024 18.9× (38.54%)
FY2023 30.7× 50.57%
FY2022 20.4× 5.64%
FY2021 19.3× 16.27%
FY2020 16.6× (19.37%)
FY2019 20.6× 56.47%
FY2018 13.2× 7.85%
FY2017 12.2× 2.60%
FY2016 11.9× (12.27%)

Quarterly newest first

Period EV/FCF Change
Jun 2026 24.5× (14.93%)
Mar 2026 28.8× (0.28%)
Dec 2025 28.9× 62.95%
Sep 2025 17.7× (9.07%)
42 more quarters

Against its own ten years

Low 10.7× High 46.5×
Ten-year median 17.5×
Current reading's percentile 86

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on AMGN